Bristol Myers Squibb: The Comeback Is Unfolding [Seeking Alpha]
Bristol-Myers Squibb Company (BMY)
Last bristol-myers squibb company earnings: 2/6 07:05 am
Check Earnings Report
US:NYSE Investor Relations:
bms.com/investors.html
Company Research
Source: Seeking Alpha
Bristol Myers Squibb's high debt levels add to the financial strain, requiring strategic measures to survive and maintain its position in the market. But I'd not prematurely bury BMY's prospects: Perhaps growth is not exactly what this stock is worth buying for, but the value it holds seems to be more durable. The current undervaluation suggests the potential for a further rise in BMY stock, especially considering recent positive developments. BMY remains undervalued by approximately 14.2%, excluding its dividend yield of 4.56%. By the end of 2024 or early 2025, I expect a total return of ~20% on the current stock price. This is my price target, which allows me to initiate coverage of BMY with a "Buy" rating. I do much more than just articles at Beyond the Wall Investing: Members get access to model portfolios, regular updates, a chat room, and more. Learn More » Intro & Thesis Bristol Myers Squibb Company NYSE: BMY ) is one of the largest pharmaceutical companies in the
Show less
Read more
Impact Snapshot
Event Time:
BMY
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
BMY alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
BMY alerts
High impacting Bristol-Myers Squibb Company news events
Weekly update
A roundup of the hottest topics
BMY
News
- Bristol-Myers Squibb (NYSE: BMY) had its price target lowered by analysts at BMO Capital Markets from $55.00 to $48.00. They now have a "market perform" rating on the stock.MarketBeat
- Bristol-Myers Squibb (NYSE: BMY) had its price target lowered by analysts at Barclays PLC from $51.00 to $43.00. They now have an "equal weight" rating on the stock.MarketBeat
- CHMP Adopts Positive Opinion Recommending Approval of Bristol Myers Squibb's Opdivo® (nivolumab) in Combination with Cisplatin and Gemcitabine for the First-Line Treatment of Adult Patients with Unresectable or Metastatic Urothelial Carcinoma [Yahoo! FinYahoo! Fin
- CHMP Adopts Positive Opinion Recommending Approval of Bristol Myers Squibb’s Opdivo® (nivolumab) in Combination with Cisplatin and Gemcitabine for the First-Line Treatment of Adult Patients with Unresectable or Metastatic Urothelial CarcinomaBusiness Wire
- Bristol-Myers Squibb Stock: Gloomy Q1 Earnings Trigger Justified Sell-Off [Seeking Alpha]Seeking Alpha
BMY
Earnings
- 4/25/24 - Miss
BMY
Sec Filings
- 4/25/24 - Form 10-Q
- 4/25/24 - Form 8-K
- 4/22/24 - Form DEFA14A
- BMY's page on the SEC website